Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

Additional Metadata
Keywords	Crohn's disease, inflammatory bowel disease, infliximab
Persistent URL	doi.org/10.1002/ibd.22902, hdl.handle.net/1765/89285
Journal	Inflammatory Bowel Diseases
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Katz, L, Gisbert, J.P, Manoogian, B, Lin, K, Steenholdt, C, Mantzaris, G.J, … Ben-Horin, S. (2012). Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflammatory Bowel Diseases, 18(11), 2026–2033. doi:10.1002/ibd.22902

Publication